Pfizer und BioNTech erhalten die erste US-Notfallzulassung für COVID-19-Impfung von Kindern im Alter von 5 bis 11 Jahren durch die FDA
29 oct. 2021 17h45 HE | BioNTech SE
Die Notfallzulassung (Emergency Use Authorization, „EUA“) basiert auf klinischen Daten, die ein vorteilhaftes Sicherheitsprofil und einen hohen Impfschutz von 90,7 % bei Kindern im Alter von 5 bis 11...
Pfizer And BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs
28 oct. 2021 06h58 HE | BioNTech SE
Doses expected to be delivered by April 2022 NEW YORK and MAINZ, GERMANY, October 28, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has...
Pfizer und BioNTech beliefern U.S.-Regierung mit 50 Millionen weiteren Kinderimpfdosen des COVID-19-Impfstoffs zur Vorbereitung auf zukünftigen Bedarf
28 oct. 2021 06h58 HE | BioNTech SE
Impfdosen werden vermutlich bis April 2022 geliefert NEW YORK und MAINZ, Deutschland, 28. Oktober 2021 — Pfizer Inc. (NYSE: PFE, “Pfizer”) und BioNTech SE (Nasdaq: BNTX, “BioNTech”) gaben heute...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years
26 oct. 2021 18h19 HE | BioNTech SE
Committee reviewed clinical data showing a favorable safety profile and high vaccine efficacy of 90.7% in children 5 to <12 years of age during a period when Delta was the prevalent strain10-µg...
On Pfizer CEO Albert Bourla’s Birthday, Medical Students and Activists from Health GAP, Rise and Resist, CPD Action and More Protest at His Home to Demand Equitable Global Access to COVID-19 Vaccines
21 oct. 2021 17h12 HE | Health GAP
SCARSDALE, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- On Pfizer CEO Albert Bourla’s birthday, medical students and activists held a mock celebration by placing a faux “Pfizer graveyard” outside...
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
21 oct. 2021 06h45 HE | BioNTech SE
First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain In...
Daten aus Phase-3-Studie von Pfizer und BioNTech zeigen hohe Wirksamkeit von COVID-19-Auffrischungsimpfung
21 oct. 2021 06h45 HE | BioNTech SE
Die ersten Ergebnisse einer randomisierten, kontrollierten COVID-19 Impfstoff-Auffrischungsstudie zeigen eine relative Impfstoffwirksamkeit von 95,6 % gegen COVID-19 in einem Zeitraum, in dem Delta...
Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union
04 oct. 2021 12h10 HE | BioNTech SE
NEW YORK and MAINZ, Germany, October 4, 2021—Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP)...
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für COVID-19-Auffrischungsimpfung in der Europäischen Union
04 oct. 2021 12h10 HE | BioNTech SE
NEW YORK, USA und MAINZ, Deutschland, 4. Oktober 2021—Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel...
Scientists & Academics, led by PrEP4All and Right to Health Action, demand global vaccine program at homes of Biden Chief of Staff and Moderna CEO
29 sept. 2021 17h30 HE | PrEP4All
“Biden’s failed COVID summit was our last straw,” say scientists who held dual press conferences at the homes of White House Chief of Staff Ron Klain and Moderna CEO Stephane Bancel. Speakers at both...